Elena A. Pyadushkina
Elena A. Pyadushkina has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Elena V. Derkach
National Center for Healthcare Technology Assessment
7 shared publications - E. E. Yagnenkova
National Center for Health Technology Assessment
4 shared publications - Victoria I. Ignatyeva
National Medical Research Center for Therapy and Preventive Medicine; Russian Medical Academy of Continuous Professional Education
3 shared publications - A. S. Mokrova
National Center for Health Technology Assessment
1 shared publication A. V. Palekhov
Stavropol State Medical University; Russian Association for the Study of Pain; Russian Association of Palliative Medicine
1 shared publication- Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
1 shared publication
Latest Publications
- Open Access
- 13 February 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (1) , 35-43
New possibilities for the treatment of systemic lupus erythematosus. How much does the effect cost?
Our previous study has shown that the new biologic disease-modifying antirheumatic drug (bDMARD) anifrolumab (AFM) can be considered as a cost-effective alternative to belimumab (BLM) in the treatment of systemic lupus erythematosus (SLE). Following a review by the Commission of the Ministry of Health of Russia, AFM was recommended for inclusion in the List of vital and Essential Drugs (VED).Objective: to conduct a clinical and economic analysis (CEA) of the use of bDMARD for the treatment of adult patients with moderate to severe SLE, to update the previously conducted CEA considering changing circumstances, including populational changes, price characteristics and law in the context of the Russian healthcare system, and to assess the impact of changes.Material and methods. The CEA was conducted from a healthcare system perspective and was based on the results of an indirect comparison of the efficacy of AFM and BLM drugs using a cost-effectiveness analysis. The costs of drug therapy with the compared bDMARDs for one year, the cost-effectiveness ratio and the incremental indicator of cost-effectiveness growth were calculated. Drug prices were calculated based on the register of maximum retail prices for drugs from the VED. A comparison of the main results of the analysis is presented.Results and discussion. The results of the indirect comparison of efficacy showed statistically significant advantages of AFM over BLM according to the SRI-4 criterion: odds ratio – 2.61 (95% confidence interval 1.22–5.58). The cost of therapy for one patient for 52 weeks, recalculated considering the changed indicators, for AFM in combination with standard therapy was 655.5 thousand rubles, for BLM – 622 thousand rubles, the difference in cost was 5.1%. When prescribing AFM, the cost of the effect (achieving a response to therapy according to the SRI-4 criterion) in one patient was 1181 thousand rubles, which is 38.6% lower than when using BLM (1924 thousand rubles). The additional cost of achieving a response according to SRI-4 in one additional patient for AFM compared to BLM amounted to 144 thousand rubles, which is significantly less than the previously calculated similar indicator – 3.4 million rubles.Conclusion. The CEA, considering the current data allows us to conclude that the use of AFM in patients with moderate to severe SLE is economically feasible within the framework of the Russian healthcare system. The expansion of the VED list by including new, more effective and economically justifiable options, and registration of maximum retail prices will increase the availability of SLE therapy, reduce the financial burden on the budgets of regions of the Russian Federation and enable more patients to receive the necessary treatment.
- 13 February 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (1) , 35-43
Open AccessNew possibilities for the treatment of systemic lupus erythematosus. How much does the effect cost?
Our previous study has shown that the new biologic disease-modifying antirheumatic drug (bDMARD) anifrolumab (AFM) can be considered as a cost-effective alternative to belimumab (BLM) in the treatment of systemic lupus erythematosus (SLE). Following a review by the Commission of the Ministry of Health of Russia, AFM was recommended for inclusion in the List of vital and Essential Drugs (VED).Objective: to conduct a clinical and economic analysis (CEA) of the use of bDMARD for the treatment of adult patients with moderate to severe SLE, to update the previously conducted CEA considering changing circumstances, including populational changes, price characteristics and law in the context of the Russian healthcare system, and to assess the impact of changes.Material and methods. The CEA was conducted from a healthcare system perspective and was based on the results of an indirect comparison of the efficacy of AFM and BLM drugs using a cost-effectiveness analysis. The costs of drug therapy with the compared bDMARDs for one year, the cost-effectiveness ratio and the incremental indicator of cost-effectiveness growth were calculated. Drug prices were calculated based on the register of maximum retail prices for drugs from the VED. A comparison of the main results of the analysis is presented.Results and discussion. The results of the indirect comparison of efficacy showed statistically significant advantages of AFM over BLM according to the SRI-4 criterion: odds ratio – 2.61 (95% confidence interval 1.22–5.58). The cost of therapy for one patient for 52 weeks, recalculated considering the changed indicators, for AFM in combination with standard therapy was 655.5 thousand rubles, for BLM – 622 thousand rubles, the difference in cost was 5.1%. When prescribing AFM, the cost of the effect (achieving a response to therapy according to the SRI-4 criterion) in one patient was 1181 thousand rubles, which is 38.6% lower than when using BLM (1924 thousand rubles). The additional cost of achieving a response according to SRI-4 in one additional patient for AFM compared to BLM amounted to 144 thousand rubles, which is significantly less than the previously calculated similar indicator – 3.4 million rubles.Conclusion. The CEA, considering the current data allows us to conclude that the use of AFM in patients with moderate to severe SLE is economically feasible within the framework of the Russian healthcare system. The expansion of the VED list by including new, more effective and economically justifiable options, and registration of maximum retail prices will increase the availability of SLE therapy, reduce the financial burden on the budgets of regions of the Russian Federation and enable more patients to receive the necessary treatment.
- 8 December 2023
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 45 (4)
Cost-effectiveness analysis of anifrolumab therapy in patients with systemic lupus erythematosus in the Russian Federation
Objective. Cost-effectiveness analysis of anifrolumab therapy in adults with moderate-to-severe systemic lupus erythematosus in the Russian Federation. Material and methods. We performed cost-effectiveness analysis to assess incremental cost-effectiveness ratio (ICER) for anifrolumab compared to belimumab in addition to standard therapy. Considering the results of indirect comparison, we established the criteria of effectiveness. Analysis of costs was based on government procurement of drugs and registered prices of drugs from the list of vital and essential drugs. Dosages of drugs were determined in accordance with instructions and clinical recommendations. Finally, we performed a sensitivity analysis varying the input parameters. Results. Anifrolumab has a significant advantage in effectiveness compared to belimumab. The odds ratio for response to therapy (SRI-4 criterion) is 2.61 (95% CI 1.22—5.58). The cost of 52-week anifrolumab therapy in addition to standard therapy is 1.3 million rubles per a patient, the cost of belimumab therapy — 0.62 million rubles. Additional costs per a patient with SRI-4 response (ICER) amounted to 3.49 million rubles when using anifrolumab compared to belimumab. This value is lower than ICER for belimumab in addition to standard therapy compared to standard therapy (5.08 million rubles). Sensitivity analysis demonstrates robustness of results to varyability of input values. Conclusion. Clinical effectiveness of anifrolumab therapy is significantly higher compared to belimumab according to SRI-4 criterion, but this therapy requires greater costs. Incremental cost for achieving SRI-4 response in 1 additional patient is 31.15% lower for anifrolumab compared to belimumab than for belimumab compared to standard therapy. Therefore, anifrolumab therapy is economically feasible in patients with moderate-to-severe systemic lupus erythematosus.
- 8 December 2023
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 45 (4)
Cost-effectiveness analysis of anifrolumab therapy in patients with systemic lupus erythematosus in the Russian Federation
Objective. Cost-effectiveness analysis of anifrolumab therapy in adults with moderate-to-severe systemic lupus erythematosus in the Russian Federation. Material and methods. We performed cost-effectiveness analysis to assess incremental cost-effectiveness ratio (ICER) for anifrolumab compared to belimumab in addition to standard therapy. Considering the results of indirect comparison, we established the criteria of effectiveness. Analysis of costs was based on government procurement of drugs and registered prices of drugs from the list of vital and essential drugs. Dosages of drugs were determined in accordance with instructions and clinical recommendations. Finally, we performed a sensitivity analysis varying the input parameters. Results. Anifrolumab has a significant advantage in effectiveness compared to belimumab. The odds ratio for response to therapy (SRI-4 criterion) is 2.61 (95% CI 1.22—5.58). The cost of 52-week anifrolumab therapy in addition to standard therapy is 1.3 million rubles per a patient, the cost of belimumab therapy — 0.62 million rubles. Additional costs per a patient with SRI-4 response (ICER) amounted to 3.49 million rubles when using anifrolumab compared to belimumab. This value is lower than ICER for belimumab in addition to standard therapy compared to standard therapy (5.08 million rubles). Sensitivity analysis demonstrates robustness of results to varyability of input values. Conclusion. Clinical effectiveness of anifrolumab therapy is significantly higher compared to belimumab according to SRI-4 criterion, but this therapy requires greater costs. Incremental cost for achieving SRI-4 response in 1 additional patient is 31.15% lower for anifrolumab compared to belimumab than for belimumab compared to standard therapy. Therefore, anifrolumab therapy is economically feasible in patients with moderate-to-severe systemic lupus erythematosus.
- Open Access
- 19 July 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (2) , 236-247
Analysis of social and economic aspects of using prolonged forms of opioid analgesics for the treatment of chronic pain syndrome in cancer patients
Background. The therapy of chronic pain in cancer patients is a highly topical issue for the modern health care system. Intense pain syndrome involves the prescription of strong opioid analgesics (ОА), most of which are classified as narcotic drugs and are under strict governmental control. In this situation, increasing the use of drugs that are equivalent in dosages to morphine and do not require a special narcotic drug prescription may increase the availability of pain relief for cancer patients and will be less associated with drug addiction.Objective: to analyze the regulatory, organizational, clinical, and economic criteria that determine the choice and influence the prescription of strong ОА for adequate pain relief in cancer patients with chronic pain syndrome (CPS). Material and methods. The article determines legal and regulatory framework regulating the sphere of providing patients with ОА, presents an expert evaluation of existing barriers that limit the availability of adequate pain treatment, and shows ways to solve these issues. We present the results of an original Russian clinical and economic study evaluating the use of prolonged forms of ОА (tapentadol and morphine) for the treatment of moderate and severe CPS in patients with cancer in the Russian healthcare system. The evidence for comparative clinical efficiency and safety of ОА under consideration is analyzed. The costs of therapy with the drugs in equivalent dosages that provide 1 year of adequate analgesia for intensive CPS in oncology patients are compared.Results. Differences in the regulatory status of opioids, including requirements for prescribing, storage, record keeping, and use, were shown to affect the availability of pain medication. According to a systematic review of the comparative efficiency and safety of prolonged forms of ОА in the therapy of cancer patients with moderate and severe CPS and a meta-analysis of randomized controlled trials, no differences were found for any of the outcomes studied in the tapentadol and morphine groups: frequency of achieving pain control – risk ratio (RR) 0.88 (95% confidence interval (CI) 0.78–1.00), frequency of using emergency (additional) pain relief – RR 1.16 (95% CI 0.95–1.42), frequency of gastrointestinal adverse events – RR 0.82 (95% CI 0.60–1.12). This suggests comparable efficiency and safety of the drugs. The difference in average cost of 1 patient course of therapy for 1 year between tapentadol and morphine was 17,653.02 rubles (–16.8%). Additional funds released in case of treating the cohort of 100 patients with tapentadol instead of morphine made 1,765,301.96 rubles, which means 20 more patients could be treated with tapentadol for 1 year.Conclusion. The use of modern effective non-invasive forms of ОА (tapentadol in particular) that have no restrictions imposed by regulatory documents on narcotic drugs prescription will increase availability, as well as reduce costs of adequate therapy of moderate and severe CPS in patients with cancer as compared to the use of equivalent daily doses of morphine.
- 19 July 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (2) , 236-247
Open AccessAnalysis of social and economic aspects of using prolonged forms of opioid analgesics for the treatment of chronic pain syndrome in cancer patients
Background. The therapy of chronic pain in cancer patients is a highly topical issue for the modern health care system. Intense pain syndrome involves the prescription of strong opioid analgesics (ОА), most of which are classified as narcotic drugs and are under strict governmental control. In this situation, increasing the use of drugs that are equivalent in dosages to morphine and do not require a special narcotic drug prescription may increase the availability of pain relief for cancer patients and will be less associated with drug addiction.Objective: to analyze the regulatory, organizational, clinical, and economic criteria that determine the choice and influence the prescription of strong ОА for adequate pain relief in cancer patients with chronic pain syndrome (CPS). Material and methods. The article determines legal and regulatory framework regulating the sphere of providing patients with ОА, presents an expert evaluation of existing barriers that limit the availability of adequate pain treatment, and shows ways to solve these issues. We present the results of an original Russian clinical and economic study evaluating the use of prolonged forms of ОА (tapentadol and morphine) for the treatment of moderate and severe CPS in patients with cancer in the Russian healthcare system. The evidence for comparative clinical efficiency and safety of ОА under consideration is analyzed. The costs of therapy with the drugs in equivalent dosages that provide 1 year of adequate analgesia for intensive CPS in oncology patients are compared.Results. Differences in the regulatory status of opioids, including requirements for prescribing, storage, record keeping, and use, were shown to affect the availability of pain medication. According to a systematic review of the comparative efficiency and safety of prolonged forms of ОА in the therapy of cancer patients with moderate and severe CPS and a meta-analysis of randomized controlled trials, no differences were found for any of the outcomes studied in the tapentadol and morphine groups: frequency of achieving pain control – risk ratio (RR) 0.88 (95% confidence interval (CI) 0.78–1.00), frequency of using emergency (additional) pain relief – RR 1.16 (95% CI 0.95–1.42), frequency of gastrointestinal adverse events – RR 0.82 (95% CI 0.60–1.12). This suggests comparable efficiency and safety of the drugs. The difference in average cost of 1 patient course of therapy for 1 year between tapentadol and morphine was 17,653.02 rubles (–16.8%). Additional funds released in case of treating the cohort of 100 patients with tapentadol instead of morphine made 1,765,301.96 rubles, which means 20 more patients could be treated with tapentadol for 1 year.Conclusion. The use of modern effective non-invasive forms of ОА (tapentadol in particular) that have no restrictions imposed by regulatory documents on narcotic drugs prescription will increase availability, as well as reduce costs of adequate therapy of moderate and severe CPS in patients with cancer as compared to the use of equivalent daily doses of morphine.
- Open Access
- 15 December 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (12) , 1516-1521
The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation
Aim. To analyze the features of drugs provision for special groups of treatment-nave HIV-infected patients initiating antiretroviral treatment with fixed dose combination (FDC) for once-daily single-tablet regimen, in Russian healthcare setting. Materials and methods. We studied the regulatory legal documents governing the provision of antiretroviral drugs in Russia and analyzed the Russian Program of State Guarantees to determine the inclusion of the investigated FDCs in the lists of regional benefits, as well as regional and federal procurement of these drugs in 2020 and 2021. We compared costs of first line therapy for special groups using FDCs regimens per year in case of regional purchases or centralized purchases. Results. It was show that doravirin/tenofovir/lamivudine was the least expensive in 2020 and in 2021 among new FDCs form drugs. Worth 325.8 and 323.9 thousand rubles. per patient per year. Тhe most expensive was bictegravir/tenofovir alafenamide/emtricitabine (401.6 and 439.9 thousand rubles, respectively). In case of Ministry of Health centralized purchases, the costs of new FDCs (doravirin/tenofovir/lamivudine and bictegravir/tenofovir alafenamide/emtricitabine), included in Vital and Essential drug list (VEDL) in 2022, will amount to 151,2 and 191.4 thousand rubles respectively, which is 52.9% and 40.4% lower than the cost per course of rilpivirine/tenofovir/emtricitabine. Conclusion. The inclusion of new effective and economical FDCs the whole scheme in one tablet once-daily in VEDL, expands the possibilities of simplify and effective first-line therapy for special groups of HIV-infected patients, as well as reduce the financial burden on the Program of State Guarantees budget and increases treatment coverage. All of this corresponds to the goals of the State Strategy to Combat the Spread of HIV in Russian Federation.
- 15 December 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (12) , 1516-1521
Open AccessThe analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation
Aim. To analyze the features of drugs provision for special groups of treatment-nave HIV-infected patients initiating antiretroviral treatment with fixed dose combination (FDC) for once-daily single-tablet regimen, in Russian healthcare setting. Materials and methods. We studied the regulatory legal documents governing the provision of antiretroviral drugs in Russia and analyzed the Russian Program of State Guarantees to determine the inclusion of the investigated FDCs in the lists of regional benefits, as well as regional and federal procurement of these drugs in 2020 and 2021. We compared costs of first line therapy for special groups using FDCs regimens per year in case of regional purchases or centralized purchases. Results. It was show that doravirin/tenofovir/lamivudine was the least expensive in 2020 and in 2021 among new FDCs form drugs. Worth 325.8 and 323.9 thousand rubles. per patient per year. Тhe most expensive was bictegravir/tenofovir alafenamide/emtricitabine (401.6 and 439.9 thousand rubles, respectively). In case of Ministry of Health centralized purchases, the costs of new FDCs (doravirin/tenofovir/lamivudine and bictegravir/tenofovir alafenamide/emtricitabine), included in Vital and Essential drug list (VEDL) in 2022, will amount to 151,2 and 191.4 thousand rubles respectively, which is 52.9% and 40.4% lower than the cost per course of rilpivirine/tenofovir/emtricitabine. Conclusion. The inclusion of new effective and economical FDCs the whole scheme in one tablet once-daily in VEDL, expands the possibilities of simplify and effective first-line therapy for special groups of HIV-infected patients, as well as reduce the financial burden on the Program of State Guarantees budget and increases treatment coverage. All of this corresponds to the goals of the State Strategy to Combat the Spread of HIV in Russian Federation.
- Open Access
- 27 July 2021
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 14 (2) , 136-150
Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting
Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured remains open.Objective: to assess the cost of triplets of targeted drugs ixazomib, carfilzomib, elotuzumab and daratumumab with lenalidomide and dexamethasone used in the treatment of RRMM, and to determine possible payment options for this therapy at the level of the Russian Federation subjects.Material and methods. The cost of an annual course of treatment with the studied regimens with centralized purchases and the cost of targeted drugs per hospitalization case were calculated based on the maximum registered prices, recommended doses and treatment regimens. The normative legal acts regulating the payment of drug therapy for multiple myeloma were analyzed and possible financing channels and their limitations were identified. Using the example of the Volgograd and Saratov Regions, tariffs under the compulsory medical insurance system were calculated and their sufficiency in covering the cost of targeted therapy was estimated.Results. The cost of an annual course of triplet therapy per patient in the case of centralized procurement of drugs ranged from 5.51 million rubles (regimen with ixazomib) up to 8.03 million rubles (regimen with carfilzomib). The cost per hospitalization, depending on the number of doses, ranged from 80,667–242,000 rubles (ixazomib, 1–3 doses) in the Saratov Region up to 239,618–958,472 rubles (daratumumab, 1–4 doses) in the Volgograd Region. Possible reimbursement channels are High-Cost Nosologies (HCN), Obligatory Medical Insurance (OMI) and Regional Drug Coverage (RDC) programs, nevertheless triplet therapy cannot be purchased via the single channel and the combination of them is required. It has been shown that, in most cases, the costs for a case of targeted drug treatment in studied regions are covered by the average tariff for the corresponding diagnosis-related group (DRG), except for cases with a maximum duration in a day hospital setting. An analysis of the RDC lists and the procurement of drugs in the studied regimens at the expense of regional budgets showed that lenalidomide, ixazomib, carfilzomib, elotuzumab and daratumumab are included in the restrictive list in regions 77, 74, 66, 63 and 47, but they are purchased only in regions 15, 24, 6, 4 and 6, respectively.Conclusion. The use of a triplet with ixazomib is characterized by the lowest costs, which indicates its greater economic attractiveness relative to carfilzomib, daratumumab and elotuzumab in the treatment of patients with RRMM. The tariffs established in the current DRG model retain the possibility of paying for treatment with the high-cost medicines at the expense of the OMI funds in combination with the HCN or RDC programs. There are reasons to believe that the expansion of the list of 14 HCN program will increase the provision of patients with highly effective therapy and also reduce the financial burden on the regions.
- 27 July 2021
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 14 (2) , 136-150
Open AccessOrganizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting
Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured remains open.Objective: to assess the cost of triplets of targeted drugs ixazomib, carfilzomib, elotuzumab and daratumumab with lenalidomide and dexamethasone used in the treatment of RRMM, and to determine possible payment options for this therapy at the level of the Russian Federation subjects.Material and methods. The cost of an annual course of treatment with the studied regimens with centralized purchases and the cost of targeted drugs per hospitalization case were calculated based on the maximum registered prices, recommended doses and treatment regimens. The normative legal acts regulating the payment of drug therapy for multiple myeloma were analyzed and possible financing channels and their limitations were identified. Using the example of the Volgograd and Saratov Regions, tariffs under the compulsory medical insurance system were calculated and their sufficiency in covering the cost of targeted therapy was estimated.Results. The cost of an annual course of triplet therapy per patient in the case of centralized procurement of drugs ranged from 5.51 million rubles (regimen with ixazomib) up to 8.03 million rubles (regimen with carfilzomib). The cost per hospitalization, depending on the number of doses, ranged from 80,667–242,000 rubles (ixazomib, 1–3 doses) in the Saratov Region up to 239,618–958,472 rubles (daratumumab, 1–4 doses) in the Volgograd Region. Possible reimbursement channels are High-Cost Nosologies (HCN), Obligatory Medical Insurance (OMI) and Regional Drug Coverage (RDC) programs, nevertheless triplet therapy cannot be purchased via the single channel and the combination of them is required. It has been shown that, in most cases, the costs for a case of targeted drug treatment in studied regions are covered by the average tariff for the corresponding diagnosis-related group (DRG), except for cases with a maximum duration in a day hospital setting. An analysis of the RDC lists and the procurement of drugs in the studied regimens at the expense of regional budgets showed that lenalidomide, ixazomib, carfilzomib, elotuzumab and daratumumab are included in the restrictive list in regions 77, 74, 66, 63 and 47, but they are purchased only in regions 15, 24, 6, 4 and 6, respectively.Conclusion. The use of a triplet with ixazomib is characterized by the lowest costs, which indicates its greater economic attractiveness relative to carfilzomib, daratumumab and elotuzumab in the treatment of patients with RRMM. The tariffs established in the current DRG model retain the possibility of paying for treatment with the high-cost medicines at the expense of the OMI funds in combination with the HCN or RDC programs. There are reasons to believe that the expansion of the list of 14 HCN program will increase the provision of patients with highly effective therapy and also reduce the financial burden on the regions.
- Open Access
- 18 February 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (1) , 119-127
Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system
Objective: to evaluate the economic impact of the use of various biologic disease-modifying antirheumatic drugs (bDMARDs) from the group of inhibitors of interleukins (iIL) 12/23 and iIL17 in adult patients with psoriatic arthritis (PsA) with insufficient response to therapy with TNFα inhibitors (TNFα inhibitors).Patients and methods. A Microsoft Excel model has been developed, it allows to calculate the average cost of treatment of 1 patient with PsA who needs a second-line bDMARD from the iIL12/23 or iIL17 group. Only direct medical costs (drug costs) were considered. Cost minimization analysis and budget impact analysis were carried out.Results and discussion. The results of a network meta-analysis demonstrate no statistically significant differences in efficacy and safety between ixekizumab (IXE) and secukinumab (SEC) and superiority SEC over ustekinumab when used in adult patients with active PsA with insufficient response to or intolerance of previous therapy with synthetic disease-modifying antirheumatic drugs or TNFα inhibitors. The analysis of cost minimization showed that the total cost of 1 patient managing for 1 year using IXE is 26% lower than treatment with SEC: on a 2 year horizon, the difference is 27%. Analysis of the impact on the budget revealed that on the horizon of 1 year the simulated distribution will lead to budget savings of 16,796,131 rubles, which will allow additional treatment of 17 patients with IXE, after 2 years the budget savings will amount to 39,289,373 rubles, which will allow to treat additionally 52 patients. The sensitivity analysis confirmed the robustness of the study results.Conclusion. Thus, in adult patients with PsA requiring second-line bDMARDs, the use of IXE is more effective than the use of SEC and provides reduction in direct medical costs. The use of IXE will not have a significant impact on costs under the State Guarantee Program, but it can increase the availability of bDMARDs in patients with active PsA who have not responded to the previous therapy, without increasing the budget.
- 18 February 2021
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (1) , 119-127
Open AccessCost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system
Objective: to evaluate the economic impact of the use of various biologic disease-modifying antirheumatic drugs (bDMARDs) from the group of inhibitors of interleukins (iIL) 12/23 and iIL17 in adult patients with psoriatic arthritis (PsA) with insufficient response to therapy with TNFα inhibitors (TNFα inhibitors).Patients and methods. A Microsoft Excel model has been developed, it allows to calculate the average cost of treatment of 1 patient with PsA who needs a second-line bDMARD from the iIL12/23 or iIL17 group. Only direct medical costs (drug costs) were considered. Cost minimization analysis and budget impact analysis were carried out.Results and discussion. The results of a network meta-analysis demonstrate no statistically significant differences in efficacy and safety between ixekizumab (IXE) and secukinumab (SEC) and superiority SEC over ustekinumab when used in adult patients with active PsA with insufficient response to or intolerance of previous therapy with synthetic disease-modifying antirheumatic drugs or TNFα inhibitors. The analysis of cost minimization showed that the total cost of 1 patient managing for 1 year using IXE is 26% lower than treatment with SEC: on a 2 year horizon, the difference is 27%. Analysis of the impact on the budget revealed that on the horizon of 1 year the simulated distribution will lead to budget savings of 16,796,131 rubles, which will allow additional treatment of 17 patients with IXE, after 2 years the budget savings will amount to 39,289,373 rubles, which will allow to treat additionally 52 patients. The sensitivity analysis confirmed the robustness of the study results.Conclusion. Thus, in adult patients with PsA requiring second-line bDMARDs, the use of IXE is more effective than the use of SEC and provides reduction in direct medical costs. The use of IXE will not have a significant impact on costs under the State Guarantee Program, but it can increase the availability of bDMARDs in patients with active PsA who have not responded to the previous therapy, without increasing the budget.
- Open Access
- 18 November 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (3) , 225-239
The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups
Diagnosis-Related Groups (DRG) for the payment for biological therapy were created at the stage of the pilot project and their coefficients of input intensity were not revised since then. The expansion of the range of genetically-engineered biological drugs (GEBD) and the development of new indications for biological therapy and new groups of expensive drugs (like selective immunodepressants, SI) determine the necessity in the differentiated payment for the therapy with GEBD and SI. However, at the federal level, this will be possible only after the approval of the clinical recommendations.Aim. The study aimed to identify possible applications of different GEBD and SI within the current provider-payment model of the Russian diagnosis-related group in terms of bronchial asthma (BA) and inflammatory bowel disease (IBD) - Crohn's disease and ulcerative colitis.Materials and methods. The expenses on GEBD and SI for one case of hospitalization were calculated and compared with the imposed tariffs. For the evaluation of the possibility of the provision of an expensive treatment within the existing DRG model, the authors modeled the distribution of patients with BA and IBD by different pharmaceutical treatment plans in the current practice and cases of an increase in the share of indications of more expensive therapy. The authors identified the number of patients that could have been treated without an increase in the costs of compulsory medical insurance (CHI). The authors proposed the subgroups for the differentiated payment for the treatment of BA and IBD with GEBD and SI.Results. Few variants of treatment with GEBD and SI were characterized by the costs of drugs that would exceed an average payment rate for DRG st36.003 and ds36.004 in 2020. In the model, an increase in the share of patients that received the most expensive drugs of all the registered GEBD and SI in the RF for the treatment of BA and IBD did not lead to an increase in the costs for CHI. It is possible to maintain the initial volume of the financing and increase the number of patients that receive GEBD and SI due to a decrease in the number of hospitalizations. The authors identified approximate values of the coefficient of input intensity (CII) for the subgroups that can be formed for the differentiated payment for pharmaceutical treatment with GEBD and SI.Conclusion. Despite the fact that without the recalculation of CII, there were numerous changed introduced into DRGs st36.003 and ds36.004 “Treatment with GEBD and SI” and the spectrum of the associated clinical situations expanded, it was possible to maintain the possibility of the payment for the therapy with different drugs, including the most expensive ones without an increase in the costs for the CHI system. Still, the results of the present study indicate the necessity in the optimization of the system of payment for medical care with genetically-engineered biologic drugs and selective immunodepressants through the implementation of a differentiated approach to the payment at the federal level.
- 18 November 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (3) , 225-239
Open AccessThe use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups
Diagnosis-Related Groups (DRG) for the payment for biological therapy were created at the stage of the pilot project and their coefficients of input intensity were not revised since then. The expansion of the range of genetically-engineered biological drugs (GEBD) and the development of new indications for biological therapy and new groups of expensive drugs (like selective immunodepressants, SI) determine the necessity in the differentiated payment for the therapy with GEBD and SI. However, at the federal level, this will be possible only after the approval of the clinical recommendations.Aim. The study aimed to identify possible applications of different GEBD and SI within the current provider-payment model of the Russian diagnosis-related group in terms of bronchial asthma (BA) and inflammatory bowel disease (IBD) - Crohn's disease and ulcerative colitis.Materials and methods. The expenses on GEBD and SI for one case of hospitalization were calculated and compared with the imposed tariffs. For the evaluation of the possibility of the provision of an expensive treatment within the existing DRG model, the authors modeled the distribution of patients with BA and IBD by different pharmaceutical treatment plans in the current practice and cases of an increase in the share of indications of more expensive therapy. The authors identified the number of patients that could have been treated without an increase in the costs of compulsory medical insurance (CHI). The authors proposed the subgroups for the differentiated payment for the treatment of BA and IBD with GEBD and SI.Results. Few variants of treatment with GEBD and SI were characterized by the costs of drugs that would exceed an average payment rate for DRG st36.003 and ds36.004 in 2020. In the model, an increase in the share of patients that received the most expensive drugs of all the registered GEBD and SI in the RF for the treatment of BA and IBD did not lead to an increase in the costs for CHI. It is possible to maintain the initial volume of the financing and increase the number of patients that receive GEBD and SI due to a decrease in the number of hospitalizations. The authors identified approximate values of the coefficient of input intensity (CII) for the subgroups that can be formed for the differentiated payment for pharmaceutical treatment with GEBD and SI.Conclusion. Despite the fact that without the recalculation of CII, there were numerous changed introduced into DRGs st36.003 and ds36.004 “Treatment with GEBD and SI” and the spectrum of the associated clinical situations expanded, it was possible to maintain the possibility of the payment for the therapy with different drugs, including the most expensive ones without an increase in the costs for the CHI system. Still, the results of the present study indicate the necessity in the optimization of the system of payment for medical care with genetically-engineered biologic drugs and selective immunodepressants through the implementation of a differentiated approach to the payment at the federal level.